Home pageDRREDDY • NSE
add
Dr. Reddy's Laboratories
Chiusura precedente
1196,00 ₹
Intervallo giornaliero
1193,30 ₹ - 1204,30 ₹
Intervallo annuale
1020,00 ₹ - 1405,90 ₹
Cap di mercato
998,63Â Mld INR
Volume medio
2,06Â Mln
Rapporto P/E
17,30
Dividendo/Prezzo
0,67%
Borsa valori principale
NSE
Notizie del mercato finanziario
PLTR
3,62%
0,36%
Dati finanziari
Conto economico
Entrate
Utile netto
| (INR) | set 2025info | Variazione Y/Y |
|---|---|---|
Entrate | 88,05Â Mld | 9,84% |
Spese di gestione | 31,90Â Mld | 7,31% |
Utile netto | 14,37Â Mld | 14,49% |
Margine di profitto netto | 16,32 | 4,21% |
Utili per azione | 17,87 | 12,91% |
EBITDA | 21,29Â Mld | -3,30% |
Aliquota fiscale effettiva | 22,25% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (INR) | set 2025info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 69,81Â Mld | 10,68% |
Totale attivo | 542,00Â Mld | 16,32% |
Totale passivo | 179,92Â Mld | 14,84% |
Patrimonio netto totale | 362,08 Mld | — |
Azioni in circolazione | 832,52 Mln | — |
Prezzo/valore contabile | 2,78 | — |
Redditività dell'attivo | 7,65% | — |
Rendimento sul capitale | 9,87% | — |
Flusso di cassa
Flusso di cassa netto
| (INR) | set 2025info | Variazione Y/Y |
|---|---|---|
Utile netto | 14,37Â Mld | 14,49% |
Liquidità di esercizio | 15,57 Mld | 67,16% |
Contanti da investimenti | -9,54Â Mld | 49,96% |
Contanti da finanziamenti | -5,32Â Mld | -132,96% |
Flusso di cassa netto | 902,00Â Mln | -85,84% |
Flusso di cassa libero | 3,25Â Mld | -17,00% |
Informazioni
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Fondazione
1984
Sito web
Dipendenti
27.811